SCHEMBL873231

SCHEMBL873231

[NH]C(=O)c1ccccc1CO

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.52
LMNA P02545 1/20 0.52
GAA P10253 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
NPC1 O15118 1/20 0.41
TP53 P04637 1/20 0.41
RAB9A P51151 1/20 0.41
APOBEC3G Q9HC16 1/20 0.41
FOLH1 Q04609 1/20 0.39
ALDH1A1 P00352 3/20 0.39
ALOX15 P16050 1/20 0.39
CYP4F2 P78329 2/20 0.38
CYP4A11 Q02928 2/20 0.38
GLS O94925 1/20 0.37
TSHR P16473 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MAPT P10636 1/20 0.37
HSD17B10 Q99714 1/20 0.37
PARP1 P09874 1/20 0.36
AKR1B1 P15121 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4261085 0.82 GABRA1 (0.44) HPGDLMNAL3MBTL1TP53FOLH1
SCHEMBL9668760 0.81 GAA (0.55) HPGDLMNAGAAL3MBTL1NPC1
SCHEMBL701634 0.80 ALDH1A1 (0.39) HPGDLMNAGAAL3MBTL1NPC1
SCHEMBL374696 0.79 FOLH1 (0.61) HPGDLMNAGAAL3MBTL1TP53
SCHEMBL9938909 0.79 HPGD (0.53) HPGDLMNAGAAL3MBTL1NPC1
SCHEMBL3135001 0.77 LMNA (0.52) HPGDLMNAGAAL3MBTL1NPC1
SCHEMBL619877 0.77 ALDH1A1 (0.52) HPGDLMNAGAAL3MBTL1NPC1
SCHEMBL8768476 0.77 FOLH1 (0.59) HPGDLMNAGAAL3MBTL1TP53
SCHEMBL12765935 0.77 HPGD (0.52) HPGDLMNAGAAL3MBTL1NPC1
SCHEMBL6043201 0.77 FOLH1 (0.59) HPGDLMNAGAAL3MBTL1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2643000-A2 THERAPEUTIC PIPERAZINES Dart Neuroscience (Cayman) Ltd (KY) 2013-10-02 EP claimed
WO-2012040258-A2 THERAPEUTIC PIPERAZINES HELICON THERAPEUTICS, INC. (US) 2012-03-29 WO claimed
US-20110065691-A1 THERAPEUTIC PIPERAZINES DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2011-03-17 US claimed
US-9624200-B2 Therapeutic piperazines DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2017-04-18 US disclosed
EP-2321277-B1 PIPECOLIC LINKER AND ITS USE FOR CHEMISTRY ON SOLID SUPPORT CENTRE NAT RECH SCIENT (FR) 2015-10-07 EP disclosed
US-20150087645-A1 THERAPEUTIC PIPERAZINES HELICON THERAPEUTICS, INC. 2015-03-26 US disclosed
US-8927546-B2 Therapeutic piperazines DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2015-01-06 US disclosed
EP-2643000-A2 THERAPEUTIC PIPERAZINES Dart Neuroscience (Cayman) Ltd (KY) 2013-10-02 EP disclosed
US-8546533-B2 Pipecolic linker and its use for chemistry on solid support CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2013-10-01 US disclosed
WO-2012040258-A2 THERAPEUTIC PIPERAZINES HELICON THERAPEUTICS, INC. (US) 2012-03-29 WO disclosed
US-20110152464-A1 PIPECOLIC LINKER AND ITS USE FOR CHEMISTRY ON SOLID SUPPORT UNIVERSITE DE MONTPELLIER I (FR) 2011-06-23 US disclosed
EP-2321277-A1 PIPECOLIC LINKER AND ITS USE FOR CHEMISTRY ON SOLID SUPPORT Centre National de la Recherche Scientifique - CNRS (FR) 2011-05-18 EP disclosed
US-20110065691-A1 THERAPEUTIC PIPERAZINES DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2011-03-17 US disclosed
EP-2226637-A1 Cross-linking agents on solid medium Centre National de la Recherche Scientifique (CNRS) (FR) 2010-09-08 EP disclosed
WO-2010023295-A1 PIPECOLIC LINKER AND ITS USE FOR CHEMISTRY ON SOLID SUPPORT CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150087645-A1 THERAPEUTIC PIPERAZINES PDE4A, PDE4B, PDE4D HPGD 1811/4885LMNA 2956/4885GAA 2428/4885
US-20110152464-A1 PIPECOLIC LINKER AND ITS USE FOR CHEMISTRY ON SOLID SUPPORT PRRC2C, VIP, PRRC2A HPGD 3421/4885LMNA 3725/4885GAA 3726/4885
US-20110065691-A1 THERAPEUTIC PIPERAZINES PDE4A, PDE4B, PDE4D HPGD 1811/4885LMNA 2956/4885GAA 2428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.